Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial

Ajay K Gopal1, Brad S Kahl2, Christopher R Flowers3

  • 1Division of Medical Oncology, Department of Medicine, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, and Seattle Cancer Care Alliance, Seattle, WA.

Blood
|March 23, 2017
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos